Investigators are assessing the potential for a specific tumor-cell population in canine hemangiosarcoma to sequester drugs within their lysosomes as a novel mechanism of drug resistance.

The goal of this study is to determine new strategies for treating canine mast cell tumors based on the targeting of a DNA-packaging protein called NDY1.

This study investigates how cytogenetic changes in canine osteosarcoma affect the duration of disease-free interval when patients are treated with amputation followed by doxorubicin and non-cytotoxic suramin.

This study will provide a molecular framework for understanding the process of miR-9-driven tumor spread in canine osteosarcoma, thereby generating potential new targets for therapy to prevent or treat tumor spread in this devastating disease.

This study evaluates a new therapeutic agent designed to inhibit the survivin protein in canine lymphoma.

This study investigates the role of citrullination in canine mammary cancer and how interfering with this process might lead to more effective anticancer treatments.

This study will determine the genetic and functional differences of eight genes that are strongly associated with congenital extrahepatic portosystemic shunts in several small dog breeds.

This study investigates the effects of topical ophthalmic prednisolone (steroid) and diclofenac (nonsteroidal anti-inflammatory drug) on diabetes mellitus regulation in client-owned dogs.

This study investigates a new therapeutic target (valosin-containing protein) for dogs with lymphoma.

This fellowship investigates genetic lesions in canine mast cell tumors using cytogenetic and expression analysis.